Nanotherapeutics for neurological disorders

The World Health Organization (WHO) report on "Neurological disorders: Public health challenges" (2006), a collaborative international survey involved 109 countries. Its projection reveals one billion population to be affected globally by 2030. The advent of nanotherapeutics has significantly leveraged the field of therapeutics with the development of nanosized materials in biomedical diagnosis and therapy of neurological diseases/disorders (ND) specifically. The inclusion of functional nanomaterials includes polymeric nanomaterials (micelle, nano-capsule, and dendrimer) and lipid-based nanoparticles (solid lipid nanoparticle and liposomes) as deliverables at the cellular and molecular levels. It has led to concerted progress in recent approaches to molecular diagnosis, gene/drug delivery, and combinatorial therapy. In this chapter, we will orient the progress and advancements in the novel approaches of nanomaterials as nanotherapeutics in the diagnosis, management, inhibition, and prospects of varied nanomaterials in the diverse application of nanomedicines in ND.